COMPANIES Novartis said on Thursday it would sell more of its core pharmaceuticals products this year – on top of the likely sales benefits to come from its new H1N1 pandemic swine flu vaccine.
But the Swiss drugs group warned that adverse currency factors could depress what should otherwise be a record year for profits and sales.
